ANIP
NASDAQANI Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$72.19-0.39 (-0.54%)
01:30 PM07:45 PM
News · 26 weeks54-36%
2026-04-192026-10-11
Mix2690d
- Insider14(54%)
- Other4(15%)
- SEC Filings3(12%)
- Earnings2(8%)
- Analyst2(8%)
- Leadership1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by ANI Pharmaceuticals Inc.4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSEC Form 4 filed by ANI Pharmaceuticals Inc.4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- PRANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual MeetingTrial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline in CST with statistical significance1 at 6 months, and these changes were maintained at 24 months (a key secondary endpoint)The most common adverse events reported were consistent with prior trials of fluocinolone acetonide intravitreal implant 0.18 mgStudy evaluated patients with chronic NIU-PS in the U.S.; most patients in the study were treated by retina specialists PRINCETON, N.J., Oct. 12, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that both 6-month and 24-month data from SYNCHRONICITY, its Phase 4, open-label,
- INSIDERSVP & CFO Carey Stephen P. sold $208,050 worth of shares (2,850 units at $73.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,993 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- PRANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual MeetingData from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026 Post-hoc analyses of baseline characteristics and efficacy outcomes in rescued and non-rescued patients from the Phase 4 NEW DAY trial will be presented in an on-demand ePoster PRINCETON, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that data from SYNCHRONICITY, its Phase 4, open-label, single-arm clinical trial of Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye (chronic NIU-PS)
- ANALYSTOppenheimer initiated coverage on ANI PharmaOppenheimer initiated coverage of ANI Pharma with a rating of Perform
- PRANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral SuspensionPRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), for Everolimus Tablets for Oral Suspension 2mg, 3mg and 5mg. ANI’s Everolimus Tablets for Oral Suspension are the generic version of the reference listed drug (RLD) Afinitor Disperz®. "The FDA approval of Everolimus Tablets for Suspension is another example of our R&D team's continued execution on technically demanding formulations, and the launch adds further momentum to our commercial portfolio. Our U.S. focused generics business c
- INSIDERPRESIDENT & CEO Lalwani Nikhil sold $383,400 worth of shares (5,400 units at $71.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 339,089 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERDirector Thoma Jeanne sold $71,530 worth of shares (1,000 units at $71.53) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 26,762 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $35,395 worth of shares (500 units at $70.79) as part of a pre-agreed trading plan, decreasing direct ownership by 0.67% to 73,924 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- ANALYSTLeerink Partners initiated coverage on ANI Pharma with a new price targetLeerink Partners initiated coverage of ANI Pharma with a rating of Outperform and set a new price target of $104.00
- PRANI Pharmaceuticals to Present at September Investor ConferencesPRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will participate in fireside chats at the following upcoming investor conferences: Event2026 Wells Fargo Healthcare Conference DateThursday, September 10, 2026 Time1:30 p.m. ET WebcastClick here EventMorgan Stanley 24th Annual Global Healthcare Conference
- INSIDERSVP & CFO Carey Stephen P. sold $207,480 worth of shares (2,850 units at $72.80) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,843 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERDirector Gosebruch Henry O was granted 6,662 shares (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSEC Form 3 filed by new insider Gosebruch Henry O3 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERPRESIDENT & CEO Lalwani Nikhil sold $401,220 worth of shares (5,400 units at $74.30) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 344,489 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- SECANI Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
- PRANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026. Mr. Gosebruch brings over 30 years of corporate strategy, business development and finance experience across the biopharmaceutical sector. "We are excited to add Henry to our Board of Directors during this pivotal moment for the Company," stated Thomas (Tom) J. Haughey, Chairman of the Board of ANI. "His proven track record in corporate strategy and value-creating acquisitions
- INSIDERSR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $37,740 worth of shares (500 units at $75.48) as part of a pre-agreed trading plan, decreasing direct ownership by 0.67% to 74,424 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSVP, GENERICS Gutwerg Ori sold $243,474 worth of shares (3,162 units at $77.00), decreasing direct ownership by 4% to 75,534 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- SECSEC Form 10-Q filed by ANI Pharmaceuticals Inc.10-Q - ANI PHARMACEUTICALS INC (0001023024) (Filer)
- SECANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
- PRANI Pharmaceuticals Reports Record Second Quarter 2026 Financial ResultsQuarterly net revenues of $266.0 million, an increase of 25.9% year-over-yearPurified Cortrophin® Gel net revenues of $117.1 million, an increase of 43.5% year-over-yearQuarterly GAAP net income available to common shareholders of $24.7 million; Quarterly adjusted non-GAAP EBITDA of $71.6 million, an increase of 32.4% year-over-yearDiluted GAAP income per share of $1.05 and adjusted non-GAAP diluted earnings per share of $2.21Reaffirming 2026 guidance for total net revenue of $1,080 - $1,140 million and adjusted non-GAAP EBITDA of $285 - $300 million PRINCETON, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced financial re
- INSIDERSVP & CFO Carey Stephen P. sold $231,876 worth of shares (2,850 units at $81.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 174,693 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- PRANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ETPRINCETON, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results on Friday, August 7, 2026, at 8:00 a.m. ET. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results. To view the webcast, please click here. Links to access the webcast and conference call will also be available on the "Events & Presentations" page of the Company’s website at https://www.anipharmaceuticals.com, under
ANIP FAQ
6 questionsWhat does ANI Pharmaceuticals Inc. do?
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group...Where does ANIP stock trade?
ANI Pharmaceuticals Inc. (ANIP) is listed on NASDAQ.What sector and industry is ANIP in?
ANI Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ANIP?
ANI Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Perform on 2026-09-23.What companies are similar to ANIP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ANIP side-by-side with any of them on Quantisnow.How can I track ANIP on Quantisnow?
Quantisnow aggregates ANI Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ANIP to receive live email and push alerts on every new disclosure.